Literature DB >> 2004161

A prostaglandin analogue as a probable cause of myocardial infarction in a young woman.

E Fliers, D R Düren, P A van Zwieten.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004161      PMCID: PMC1676214          DOI: 10.1136/bmj.302.6773.416-a

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

1.  Physiologic role of coronary PGI2 and PGE2 in modulating coronary vascular response to sympathetic stimulation.

Authors:  G G Neri Serneri; G F Gensini; R Abbate; S Castellani; F Bonechi; A Dagianti; L Arata; F Fedele; C Iacoboni; D Prisco
Journal:  Am Heart J       Date:  1990-04       Impact factor: 4.749

2.  Prostaglandins and heart disease.

Authors:  R E Beamish; P K Das; M Karmazyn; N S Dhalla
Journal:  Can J Cardiol       Date:  1985-01       Impact factor: 5.223

3.  Effects of endogenously produced leukotrienes, thromboxane, and prostaglandins on coronary vascular resistance in rabbit myocardial infarction.

Authors:  A S Evers; S Murphree; J E Saffitz; B A Jakschik; P Needleman
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

  3 in total
  3 in total

Review 1.  Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology.

Authors:  A N de Groot; P W van Dongen; T B Vree; Y A Hekster; J van Roosmalen
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

2.  Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery.

Authors:  Y M Qian; R L Jones; K M Chan; A I Stock; J K Ho
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

3.  Incidence and predictors of maternal cardiovascular mortality and severe morbidity in The Netherlands: a prospective cohort study.

Authors:  Claartje M Huisman; Joost J Zwart; Jolien W Roos-Hesselink; Johannes J Duvekot; Jos van Roosmalen
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.